Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect

被引:183
|
作者
Vincent, L
Chen, W
Hong, L
Mirshahi, F
Mishal, Z
Mirshahi-Khorassani, T
Vannier, JP
Soria, J
Soria, C
机构
[1] Lab DIFEMA, UFR Med & Pharm Rouen, F-76183 Rouen, France
[2] Hop St Louis, INSERM, U553, Paris, France
[3] Hotel Dieu, Biochim Lab, Paris, France
[4] Hotel Dieu, EMI 99 12, Paris, France
关键词
anti-angiogenesis; migration; HMG-CoA reductase inhibitor; cerivastatin; RhoA; Ras;
D O I
10.1016/S0014-5793(01)02337-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent studies have suggested that inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (statins) can play a role in protection against vascular risk, which is independent of cholesterol reduction. It could act by inhibiting the synthesis of isoprenoids (farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP)), which are respectively essential for membrane attachment and biological activity of GTPases Ras and RhoA. This study demonstrates that a statin (cerivastatin) inhibits angiogenesis, This effect was due to a decrease in endothelial cell locomotion which was reversed by GGPP, It was mainly related to delocalization of RhoA from cell membrane to cytoplasm, responsible for the disorganization of actin stress fibers. Furthermore, a decrease in MMP-2 secretion, involved in cell invasion, mas also observed. This effect is rather due to Ras inhibition as it was reversed by FPP, This antiangiogenic activity could explain the beneficial effect of statins on atherosclerosis and on cancer prevention as shown by clinical studies. (C) 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 50 条
  • [21] Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia
    Kumai, T
    Oonuma, S
    Matsumoto, N
    Takeba, Y
    Taniguchi, R
    Kamio, K
    Miyazu, O
    Koitabashi, Y
    Sekine, S
    Tadokoro, M
    Kobayashi, S
    LIFE SCIENCES, 2004, 74 (17) : 2129 - 2142
  • [22] The Effect of HMG-CoA Reductase Inhibitor on Insulin Resistance in Patients Undergoing Peritoneal Dialysis
    Doh, Fa Mee
    Chang, Tae-Ik
    Koo, Hyang Mo
    Lee, Mi Jung
    Shin, Dong Ho
    Kim, Chan Ho
    Ko, Kwang Il
    Oh, Hyung Jung
    Yoo, Tae-Hyun
    Kang, Shin-Wook
    Han, Dae-Suk
    Han, Seung Hyeok
    CARDIOVASCULAR DRUGS AND THERAPY, 2012, 26 (06) : 501 - 509
  • [23] The Effect of HMG-CoA Reductase Inhibitor on Insulin Resistance in Patients Undergoing Peritoneal Dialysis
    Fa Mee Doh
    Tae-Ik Chang
    Hyang Mo Koo
    Mi Jung Lee
    Dong Ho Shin
    Chan Ho Kim
    Kwang Il Ko
    Hyung Jung Oh
    Tae-Hyun Yoo
    Shin-Wook Kang
    Dae-Suk Han
    Seung Hyeok Han
    Cardiovascular Drugs and Therapy, 2012, 26 : 501 - 509
  • [24] Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
    Mück, W
    Ochmann, K
    Rohde, G
    Unger, S
    Kuhlmann, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 53 (06) : 469 - 473
  • [25] Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs
    Suzuki, H
    Aoki, T
    Tamaki, T
    Sato, F
    Kitahara, M
    Saito, Y
    ATHEROSCLEROSIS, 1999, 146 (02) : 259 - 270
  • [26] Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells
    Ohtawa, M
    Masuda, N
    Akasaka, I
    Nakashima, A
    Ochiai, K
    Moriyasu, M
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (04) : 383 - 389
  • [27] Influence of HMG-CoA Reductase Inhibitors on Leptin-Induced Endothelial Cell Proliferation, Migration, and Capillary-Like Tube Formation
    Burgazli, K. M.
    Stein, N. I.
    Mericliler, M.
    Parahuleva, M.
    Erdogan, A.
    POSTGRADUATE MEDICINE, 2014, 126 (03) : 231 - 238
  • [28] Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity
    Swiatkowska, M
    Pawlowska, Z
    Szemraj, J
    Drzewoski, J
    Watala, C
    Cierniewski, CS
    JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 90 (04): : 337 - 344
  • [29] Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228 and its inhibitory effect on vascular smooth muscle cell growth
    Igarashi, M
    Takeda, Y
    Mori, S
    Ishibashi, N
    Komatsu, E
    Takahashi, K
    Fuse, T
    Yamamura, M
    Kubo, K
    Sugiyama, Y
    Saito, Y
    BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 (06) : 1172 - 1178
  • [30] Effect of HMG-CoA Reductase Inhibition on Vascular Smooth Muscle Cells Extracellular Matrix Production: Role of RhoA
    Palomino-Morales, Rogelio
    Perales, Sonia
    Torres, Carolina
    Linares, Ana
    Alejandre, Maria J.
    CURRENT VASCULAR PHARMACOLOGY, 2016, 14 (04) : 345 - 352